Novartis NSCLC drug LDK378 joins elite, but growing, 'breakthrough' club
This article was originally published in Scrip
Executive Summary
When the US FDA granted Novartis' investigational non-small-cell lung cancer drug LDK378 breakthrough therapy status, the highly selective anaplastic lymphoma kinase (ALK) inhibitor joined an elite, but growing, club of experimental medicines under development.